Last updated: April 28, 2026
What is isosorbide mononitrate and where is it positioned clinically?
Isosorbide mononitrate (IMN) is an oral nitrate used for angina prophylaxis and for prevention of ischemic episodes related to coronary artery disease. In clinical practice it competes in a crowded cardiovascular vasodilator and antianginal landscape that includes other nitrates (immediate- and extended-release forms, sublingual rescue products), beta-blockers, calcium channel blockers, ranolazine, and revascularization where appropriate.
IMN is widely used and typically evaluated clinically for:
- Antianginal efficacy (frequency of angina attacks)
- Exercise tolerance outcomes (time to angina or time to ischemic changes)
- Hemodynamic effects and tolerability (headache, hypotension)
What does the clinical trials landscape look like right now?
A complete, current “trials update” requires a live registry sweep. No registry query results were provided here, and no trial identifiers (e.g., NCT numbers, start dates, sponsors) were included in the prompt. Under the operating constraints, an accurate update cannot be produced.
How is the market defined for isosorbide mononitrate?
The IMN market is best modeled as a segment within:
- Cardiology antianginal therapies
- Oral nitrate therapy (prophylaxis)
- Chronic use settings (stable angina management)
Practical market drivers for IMN include:
- High prevalence of ischemic heart disease and stable angina
- Generic penetration across major markets, which compresses pricing and shifts growth to volume and mix
- Formulation strategy (extended-release vs immediate-release) that aims to smooth symptom control and improve adherence
What are the key competitive dynamics?
IMN competes on:
- Price-to-coverage in generic-heavy markets
- Form factor and dosing convenience (once-daily or multiple daily dosing schedules depending on formulation)
- Switchability with other antianginals, especially when payers and clinicians optimize combination therapy
Competitive pressure is strongest from:
- Other generic antianginal classes (beta-blockers, CCBs)
- Brand and generic antianginals with stronger perceived efficacy or guideline alignment in subpopulations
- Revascularization in appropriately selected patients, which can reduce medication burden
What is the current IP status relevance for new development?
Isosorbide mononitrate itself is an established active ingredient. Commercial differentiation in most markets typically depends on:
- Formulation IP (controlled release matrices, coating systems)
- Dosing regimens and bioequivalence-based product lifecycle management
- Local regulatory pathways for generics and follow-on versions
For investing in “new IMN” products, the decisive question is usually whether a party can secure enforceable IP around a specific formulation or delivery profile rather than the API.
What market projection is supportable?
A credible projection requires at least one of the following: a baseline market size, recent forecast sources, or registry-linked growth tied to specific pipeline products. None were provided, and no cited market-source inputs are available in the prompt. Under the operating constraints, an accurate numeric projection cannot be produced.
Data tables (hard facts only)
No registry or market-size inputs were provided in the prompt. The following tables therefore cannot be populated without introducing unsourced numbers, which violates the constraint set.
Market sizing and forecast inputs
| Item |
Required input |
Provided |
| Global market size (IMN) |
2023/2024 revenue or units |
No |
| Forecast methodology |
CAGR assumption source |
No |
| Segment split |
oral controlled-release vs others; geography |
No |
| Competitive pricing |
ASP or reimbursement trends |
No |
| Pipeline-driven uplift |
trial- or approval-linked products |
No |
Clinical trials table
| Field |
Required data |
Provided |
| NCT-linked studies |
registry results |
No |
| Trial phase distribution |
phase counts by date |
No |
| Enrollment status |
recruited/active/completed |
No |
| Endpoints |
angina frequency, exercise tolerance |
No |
| Safety findings |
headache, hypotension rates |
No |
Key Takeaways
- Isosorbide mononitrate is a mature, generic-heavy antianginal oral nitrate used for angina prophylaxis.
- A current “clinical trials update” cannot be produced from the information supplied; no trial registry data was included.
- A numeric market projection cannot be produced without baseline market figures and forecast source inputs; none were provided.
FAQs
-
What is isosorbide mononitrate used for?
It is used for angina prophylaxis to prevent ischemic episodes in coronary artery disease patients.
-
Is the product differentiated by the API or formulation?
In mature markets, differentiation is usually tied to formulation and release profile rather than new API development.
-
Who competes with isosorbide mononitrate?
It competes with other nitrates and broad antianginal classes such as beta-blockers and calcium channel blockers, plus add-on options like ranolazine depending on patient profile.
-
Can you summarize ongoing trials right now?
Not from the information provided in the prompt; no trial registry details were included.
-
Can you give a market CAGR forecast for isosorbide mononitrate?
Not without a baseline and forecast-source inputs; none were provided.
References
[1] World Health Organization. WHO Model List of Essential Medicines (for class context and established use of antianginal nitrates).
